Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the completion of the issuance of its first tranche of Scientific and Technological Innovation Bonds for 2026. The offering consists of medium-term notes with an aggregate principal amount of RMB1 billion, a term of two years, and a coupon rate of 2.4%. The bonds, named 26 Fosun Pharma MTN001 (Scientific and Technological Innovation Bond) with code 102680411, were issued at RMB100 per RMB100 in principal amount. The value date is 2 February 2026, with payment due on 2 February 2028. The leading underwriter is China Merchants Bank Co., Ltd., with joint leading underwriters including Bank of Beijing Co., Ltd., Shanghai Pudong Development Bank Co., Ltd., China Everbright Bank Company Limited, and HUA XIA BANK CO., Limited. The relevant documents are available at https://www.chinamoney.com.cn and https://www.shclearing.com.cn.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011994), on February 03, 2026, and is solely responsible for the information contained therein.